Figure 2.
csCMVi and NRM according to graft sources. Cumulative incidence of csCMVi in recipients of (A) BM, (B) PBSC, and (C) CB transplantation, and NRM in recipients of (D) BM, (E) PBSC, and (F) CB transplantation. Data in patients with letermovir prophylaxis are indicated by dotted blue lines and those in patients without CMV prophylaxis are shown with solid red lines. Black dotted lines indicate 6 months or 1 year after transplantation.